Drug Search Results
More Filters [+]

AD-E6E7

Alternative Names: ad-e6e7, ad e6e7, ade6e7
Latest Update: 2023-04-14
Latest Update Note: Clinical Trial Update

Product Description

AD-E6E7 is being developed by Turnstone Biologics for the treatment of patients with HPV-Associated Cancers. (Sourced from: https://clinicaltrials.gov/ct2/show/NCT03618953?term=AD-E6E7&draw=2&rank=1)

Mechanisms of Action: Vaccine

Novel Mechanism: No

Modality: Vaccine

Route of Administration: N/A

FDA Designation: None *

Approval Status: Not Approved

Approved Countries: None

Approved Indications: None

Known Adverse Events: None

Company: Turnstone Biologics
Company Location:
Company CEO:
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for AD-E6E7

Countries in Clinic:

Active Clinical Trial Count:

Highest Development Phases

Phase 1: Cervical Cancer|Papilloma|Oropharyngeal Cancer

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success

Kingfisher

P1

Terminated

Papilloma|Cervical Cancer|Oropharyngeal Cancer

2021-03-05

Recent News Events

Date

Type

Title